KRAS and non-small cell lung carcinoma: Examining the mechanistic action of adagrasib, preliminary pharmacodynamic and mechanistic biomarker analyses on pre- and post-treatment tumor NSCLC biopsies of 3 patients demonstrated downregulation of KRAS/MAPK pathway genes including DUSP6 and SPRY4. Furthermore, in patients with tumors containing STK11-comutations, there was minimal expression of immune transcripts such as CD4 and CD8 at baseline.